{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:04:24Z","timestamp":1758931464876,"version":"3.44.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671600","81241094"],"award-info":[{"award-number":["81671600","81241094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Polymyositis (PM) and dermatomyositis (DM) are the major subtypes of idiopathic inflammatory myopathies with heterogeneous treatment responses. This study aimed to develop a predictive model for identifying PM\/DM patients who are non-responsive to conventional therapy by assessing a range of diagnostic tools to guide individualized treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with PM\/DM from two medical centers (January 2010-December 2024) were included. Baseline and 12-week post-treatment clinical data were collected. Logistic regression was employed to develop both comprehensive and non-invasive predictive models. Model performance was validated using the area under the receiver operating characteristic curve (AUC) in internal and external test sets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The Qingdao cohort comprised 84 patients (age 57.7 \u00b1 1.5 years; 54 females [62.5%]; DM = 53, PM = 31) and the Liaocheng cohort included 22 patients (age 56.4 \u00b1 3.8 years; 15 females [68.2%]; DM = 13, PM = 9). Gender, mSUVmax, and muscle bundle atrophy were identified as independent predictive factors. The comprehensive model achieved an AUC of 0.900 (95% confidence intervals [CI]: 0.813-1.009) in the training set, demonstrating superior diagnostic performance compared to the non-invasive model. The non-invasive model yielded AUCs of 0.857 (95% CI: 0.766-0.972), 0.742 (95% CI: 0.599-0.984), and 0.765 (95% CI: 0.632-0.987) in the training, internal test, and external test sets, respectively, indicating broader applicability across different cohorts. Both models showed good discrimination and calibration, and decision curve analysis further confirmed their clinical value.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These findings suggest that predictive models based on clinical, pathological, and imaging features can effectively identify PM\/DM patients who are non-responsive to conventional therapy, potentially providing a tool for personalized treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1596858","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:30:45Z","timestamp":1758864645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive models for non-response to conventional treatment in polymyositis and dermatomyositis"],"prefix":"10.3389","volume":"12","author":[{"given":"Bo","family":"Zang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lishan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dacheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiwen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton","year":"2021","journal-title":"Intern Med J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/ddg.14267_g","article-title":"Update on dermatomyositis in adults","volume":"18","author":"Schlecht","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","article-title":"The use of low-dose Oral methotrexate in the treatment of polymyositis and dermatomyositis","volume":"1","author":"Newman","year":"1995","journal-title":"J Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: Management of Refractory Inflammatory Myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/BOR.0000000000001041","article-title":"From traditional to targeted: the changing trajectory of therapies in dermatomyositis","volume":"36","author":"Castillo","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.berh.2022.101762","article-title":"Possible future avenues for myositis therapeutics: DM, IMNM and IBM","volume":"36","author":"Connolly","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group\/Paediatric rheumatology international trials organisation collaborative initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/rheumatology\/kez040","article-title":"Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity","volume":"58","author":"Matuszak","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"152231","DOI":"10.1016\/j.semarthrit.2023.152231","article-title":"Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review","volume":"62","author":"Xie","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/PGPM.S369556","article-title":"Risk factors and predictive model for dermatomyositis associated with rapidly progressive interstitial lung disease","volume":"15","author":"Wang","year":"2022","journal-title":"Pharmgenomics Pers Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.062","article-title":"The prospective registry of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies","author":"Yu","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3899\/jrheum.220383","article-title":"A systematic review and Metaanalysis of predictors of mortality in idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"50","author":"Hannah","year":"2023","journal-title":"J Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/diagnostics13142316","article-title":"[(18)F]FDG-PET\/CT in idiopathic inflammatory myopathies: retrospective data from a Belgian cohort","volume":"13","author":"Yildiz","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/rheumatology\/ket112","article-title":"[18F]FDG uptake in proximal muscles assessed by PET\/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis\/dermatomyositis","volume":"52","author":"Tanaka","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","first-page":"570","article-title":"18F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis: a case series","volume":"30","author":"Pipitone","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s13075-014-0423-2","article-title":"Clinical value of whole-body PET\/CT in patients with active rheumatic diseases","volume":"16","author":"Yamashita","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1007\/s00330-019-06302-9","article-title":"Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis","volume":"29","author":"Martis","year":"2019","journal-title":"Eur Radiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/mus.24307","article-title":"Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy","volume":"51","author":"Van De Vlekkert","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"103185","DOI":"10.1016\/j.jaut.2024.103185","article-title":"Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathy","volume":"144","author":"Kastrati","year":"2024","journal-title":"J Autoimmun"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.24993","article-title":"Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: a single cohort study","volume":"75","author":"Jiang","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00296-024-05668-4","article-title":"Patient experiences of muscle biopsy in idiopathic inflammatory myopathies: a cross-sectional survey","volume":"44","author":"Sutu","year":"2024","journal-title":"Rheumatol Int"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"152519","DOI":"10.1016\/j.semarthrit.2024.152519","article-title":"Muscle biopsy practices in the evaluation of idiopathic inflammatory myopathies: an international survey of expert clinicians","volume":"68","author":"Maxwell","year":"2024","journal-title":"Semin Arthritis Rheum"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1596858\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:30:46Z","timestamp":1758864646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1596858\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":29,"alternative-id":["10.3389\/fmed.2025.1596858"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1596858","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1596858"}}